VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IWWM-11 2022 | Predicting patient response to BTK inhibitors using novel approaches

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the importance of using novel approaches to predict patient response to Bruton’s tyrosine kinase (BTK) inhibitor therapy. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter